The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Tumour antibody serum compositions is a key innovation area in immuno-oncology

Serum antibodies play a crucial role in both innate and adaptive immunity and in immunological memory. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker. The production of serum antibodies results from regulated differentiation of B lymphocytes into antibody secreting cells (ASCs), plasma blasts, and plasma cells.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 310+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of tumour antibody serum compositions.

Key players in tumour antibody serum compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to tumour antibody serum compositions

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
F. Hoffmann-La Roche 3006 Unlock Company Profile
Bristol-Myers Squibb 687 Unlock Company Profile
Amgen 494 Unlock Company Profile
Gilead Sciences 312 Unlock Company Profile
Merck & Co 309 Unlock Company Profile
Daiichi Sankyo 301 Unlock Company Profile
Pfizer 301 Unlock Company Profile
Regeneron Pharmaceuticals 273 Unlock Company Profile
Johnson & Johnson 253 Unlock Company Profile
C. H. Boehringer Sohn 223 Unlock Company Profile
E. Merck 217 Unlock Company Profile
AbbVie 205 Unlock Company Profile
Eli Lilly and 199 Unlock Company Profile
ImmunoGen 189 Unlock Company Profile
MacroGenics 174 Unlock Company Profile
Toray Industries 159 Unlock Company Profile
Immatics 155 Unlock Company Profile
GSK 154 Unlock Company Profile
Merrimack Pharmaceuticals 130 Unlock Company Profile
Immutep 120 Unlock Company Profile
Pierre Fabre Foundation 103 Unlock Company Profile
Mayo Clinic 100 Unlock Company Profile
AstraZeneca 93 Unlock Company Profile
Eisai 84 Unlock Company Profile
Sanofi 84 Unlock Company Profile
ADC Therapeutics 83 Unlock Company Profile
Otsuka Holdings 82 Unlock Company Profile
Cancer Research UK 77 Unlock Company Profile
Novartis 77 Unlock Company Profile
Celldex Therapeutics 76 Unlock Company Profile
Massachusetts General Hospital 76 Unlock Company Profile
Compugen 75 Unlock Company Profile
Centre National de la Recherche Scientifique 69 Unlock Company Profile
U3 Pharma 69 Unlock Company Profile
BioNTech 68 Unlock Company Profile
XOMA 68 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 61 Unlock Company Profile
Sesen Bio 59 Unlock Company Profile
Seven and Eight Biopharmaceuticals 57 Unlock Company Profile
Biocon 54 Unlock Company Profile
Nektar Therapeutics 53 Unlock Company Profile
Ono Pharmaceutical 53 Unlock Company Profile
NantWorks 53 Unlock Company Profile
Infinity Pharmaceuticals 52 Unlock Company Profile
Biogen 52 Unlock Company Profile
Vertex Pharmaceuticals 52 Unlock Company Profile
Astellas Pharma 52 Unlock Company Profile
Replimune Group 50 Unlock Company Profile
Kirin Holdings 50 Unlock Company Profile
Zymeworks 49 Unlock Company Profile

Source: GlobalData Patent Analytics

F. Hoffmann-La Roche Ltd is the leading patent filer in tumour antibody serum compositions. F. Hoffmann-La Roche (Roche) develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases.. Bristol-Myers Squibb and Amgen are among the other key patent filers in tumour antibody serum compositions.

In terms of application diversity, EpimAb Biotherapeutics is the top company, followed by Light Chain Bioscience and MediGene AG. By means of geographic reach, Atara Biotherapeutics Inc holds the top position. Immutep Ltd. and Argenx SE stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.